SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

MSI NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

COMPANY SEARCH RESULT

NOVARTIS: Click to view the issuer\'s details

Last update : 28/01/2011  >View issuer details

2019.04.23 | 13:00 | Permanent Information Releases / Notification of availability

English version HTML (w) Mail

puce Alcon to Host Trading Update for First Quarter 2019 Results - HTML (w)

2019.04.16 | 22:45 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce AveXis data reinforce effectiveness of Zolgensma® in treating spinal muscular atrophy (SMA) Type 1 - HTML (w)

2019.04.15 | 22:05 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD - HTML (w)

2019.04.09 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off - HTML (w)

2019.04.09 | 04:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Alcon Debuts as Independent, Publicly Traded Company - HTML (w)

2019.04.04 | 22:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Novartis updates on the migraine collaboration with Amgen - HTML (w)

2019.04.03 | 07:15 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Sandoz resubmits biosimilar pegfilgrastim application to US FDA - HTML (w)

2019.04.02 | 07:15 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Novartis first-in-class Cosentyx® approved in China for psoriasis patients - HTML (w)

2019.04.01 | 07:15 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Novartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM Tre - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1197